Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China; Gene Diagnostic Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China.
Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China; Gene Diagnostic Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China.
Clin Chim Acta. 2018 Jun;481:12-19. doi: 10.1016/j.cca.2018.02.015. Epub 2018 Feb 14.
Serum HBV large surface protein (HBV-LP) is an envelope protein that has a close relationship with HBV DNA level. This study is to explore the prediction value of HBV-LP in different phase of HBV infection and during antiviral therapy in chronic hepatitis B (CHB) patients.
A retrospective study was conducted in 2033 individuals, which included 1677 HBV infected patients in different phases and 356 healthy controls. HBV-LP, HBV serum markers and HBV DNA were detected by ELISA, CMIA and qRT-PCR, respectively. 85 CHB patients receiving PegIFNα or ETV were divided into virological response (VR) and partial virological response (PVR). The dynamic changes of HBV DNA and HBV-LP were observed.
The level of HBV-LP in 2033 individuals was shown as: HBeAg-positive hepatitis > HBeAg-positive infection > HBeAg-negative hepatitis > HBeAg-negative infection > healthy controls. HBV-LP was positive in all patients whose HBV DNA > 1.0E + 06 IU/ml. When HBsAg was <0.05 IU/ml or >1000 IU/ml, HBV DNAs were all negative if HBV-LP < 1.0 S/CO. When HBsAg was between 0.05 IU/ml and 1000 IU/ml, the consistency of HBV-LP with HBV DNA was 100% in case of HBV-LP > 4.0 S/CO in HBeAg-positive patients and HBV-LP > 2.0 S/CO in HBeAg-negative ones. During antiviral therapy, baseline HBV-LP was lower in VR patients than that in PVR patients. The optimal cut-off points to predict VR by baseline HBV-LP were 32.4 and 28.6 S/CO for HBeAg-positive and HBeAg-negative hepatitis patients, respectively.
HBV-LP may be a useful marker for distinguishing the different phases of HBV infection. Moreover, baseline HBV-LP level can be used for predicting VR of CHB patients.
血清 HBV 大表面蛋白（HBV-LP）是一种包膜蛋白，与 HBV DNA 水平密切相关。本研究旨在探讨 HBV-LP 在 HBV 感染不同阶段及慢性乙型肝炎（CHB）患者抗病毒治疗中的预测价值。
对 2033 例个体进行回顾性研究，其中包括 1677 例 HBV 感染不同阶段的患者和 356 例健康对照者。采用 ELISA、CMIA 和 qRT-PCR 分别检测 HBV-LP、HBV 血清标志物和 HBV DNA。85 例接受 PegIFNα或 ETV 治疗的 CHB 患者分为病毒学应答（VR）和部分病毒学应答（PVR）。观察 HBV DNA 和 HBV-LP 的动态变化。
2033 例个体的 HBV-LP 水平如下：HBeAg 阳性肝炎> HBeAg 阳性感染> HBeAg 阴性肝炎> HBeAg 阴性感染>健康对照组。HBV DNA>1.0E+06 IU/ml 的所有患者 HBV-LP 均为阳性。当 HBsAg<0.05 IU/ml 或>1000 IU/ml 时，HBV-LP<1.0 S/CO 时 HBV DNA 均为阴性。当 HBsAg 在 0.05 IU/ml 至 1000 IU/ml 之间时，在 HBeAg 阳性患者中，HBV-LP>4.0 S/CO 且在 HBeAg 阴性患者中，HBV-LP>2.0 S/CO 时，HBV-LP 与 HBV DNA 的一致性为 100%。抗病毒治疗期间，VR 患者的基线 HBV-LP 低于 PVR 患者。HBV-LP 预测 HBeAg 阳性和 HBeAg 阴性肝炎患者 VR 的最佳截断值分别为 32.4 和 28.6 S/CO。
HBV-LP 可能是区分 HBV 感染不同阶段的有用标志物。此外，基线 HBV-LP 水平可用于预测 CHB 患者的 VR。
